ACHIEVE LIFE SCIENCES, INC. (ACHV): Nasdaq/NYSE listing notice — Achieve Life Sciences receives Nasdaq delisting notice for low equity; plans to submit compliance plan

ACHIEVE LIFE SCIENCES, INC.

Stockholders' equity as of Sept 30, 2022 was $1.0M, below Nasdaq's $2.5M minimum.
Nasdaq gave 45 days (until Jan 6, 2023) to submit a plan to regain compliance.
Company expects to submit plan citing recent private offering to boost equity.
If plan accepted, Nasdaq may grant up to 180 days extension; if not, delisting possible.
No immediate effect on trading; stock continues on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ACHIEVE LIFE SCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 22, 2022, Achieve Life Sciences, Inc., a Delaware corporation (the “ Company ”), received a written notification from the Listing Qualifications staff of The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “ Stockholders’ Equity Requirement ”). The Company’s Form 10-Q for the quarter ended September 30, 2022, filed on November 14, 2022, reflect

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ACHIEVE LIFE SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-22-038292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.